4D Molecular Therapeutics Inc (FDMT) Stock Price, Quote & News

Company Profile

4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. Its lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degene...

Industry: Biotechnology

Sector: Healthcare

Phone: 510 505 2680

Website: www.4dmoleculartherapeutics.com

Address:

5858 Horton Street, Suite 455, EmeryVille, United States

AtomicAIerts Dec. 5 at 10:50 AM

$FDMT AtomicAlerts Scalp Alert Direction: SHORT Entry: $11.2 TP1: $10.5 | TP2: $9.8 | TP3: $9.1 Stop Loss: $11.8 👉 https://atomicalerts.com

0 · Reply

Iightning Dec. 5 at 5:52 AM

1ightning® Premium Options Alert (Actionable) Ticker: $FDMT Contract: Dec 19 $12C Entry: 2.62 Exit: 3.24 Return: +23.59% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Iightning Dec. 4 at 11:41 PM

1ightning® Premium Options Alert (Actionable) Ticker: $FDMT Contract: Dec 19 $12C Entry: 2.62 Exit: 3.24 Return: +23.59% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Emremumcu01 Dec. 4 at 12:24 PM

$FDMT I listened to the presentation. 2 weeks and we’re getting CF DATA . Interesting point that should be noted is that they said the drug is only for a 15 percent sub populations AS LONG AS I heard correctly because I was only Half listening.

1 · Reply

HedgeAlerts Dec. 4 at 7:35 AM

Hedge Alert Live - Protect Your Portfolio Contract: $FDMT $10.00 Put · DEC 19, 2025 Exp Entry Price: $0.45 - $1.25 Exit Price Target: $0.72 Profit Margin: +60% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

Iightning Dec. 4 at 7:21 AM

1ightning® Premium Options Alert (Actionable) Ticker: $FDMT Contract: Dec 19 $10C Entry: 2.70 Exit: 3.71 Return: +37.30% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

ReturnOfEsquire Dec. 4 at 2:03 AM

$FDMT Presentation still isn't up.

0 · Reply

Emremumcu01 Dec. 3 at 3:05 PM

$FDMT who’s tuning into the conference call today something tells me there will be interesting information shared with us

1 · Reply

grizzly3 Dec. 3 at 2:32 AM

$FDMT “Shot the bear”? More like ricochet back at caronte. Every time he calls for $40–$100, the chart answers with another leg down.

0 · Reply

LiquidThetaOptions Dec. 3 at 12:58 AM

💎 LiquidTheta® Live Actionable Trade Asset: $FDMT Contracts: $FDMT July 17, 2026 $11 Calls Scale in: $2.66- $3.25 Scale out: $10.33-$17.70 Profit Potential : 182% ROI Blended Join 💎 Here: https://liquidtheta.com

0 · Reply

4D Molecular Therapeutics, Inc. (FDMT) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 20, 2025, 8:00 AM EST - 14 days ago

4DMT to Participate in 8th Annual Evercore Healthcare Conference

Nov 17, 2025, 6:00 AM EST - 18 days ago

4DMT Appoints Kristian Humer as Chief Financial Officer

Nov 14, 2025, 4:05 PM EST - 20 days ago

4DMT Announces New Employment Inducement Grants

Nov 10, 2025, 8:00 AM EST - 24 days ago

4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

Nov 6, 2025, 4:05 PM EST - 4 weeks ago

4DMT to Participate in Jefferies 2025 London Healthcare Conference

Nov 6, 2025, 6:23 AM EST - 4 weeks ago

4DMT Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants

Nov 6, 2025, 6:00 AM EST - 4 weeks ago

4DMT Announces Positive Long-Term Data from Phase 1/2 PRISM Clinical Trial in Wet AMD Supporting 4D-150's Potential as a Backbone Therapy with Consistent and Durable Benefit over Multiple Years

Oct 30, 2025, 11:02 PM EDT - 5 weeks ago

4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific

Oct 14, 2025, 8:00 AM EDT - 7 weeks ago

4DMT to Participate in Chardan's 9th Annual Genetic Medicines Conference

Oct 13, 2025, 8:00 AM EDT - 7 weeks ago

4DMT Advances 4D-710 to Phase 2 with Additional Funding and Support from the Cystic Fibrosis Foundation

Sep 30, 2025, 5:08 AM EDT - 2 months ago

4D Molecular Therapeutics: This Gene Therapy Company May Soon Surprise Investors

Sep 9, 2025, 6:13 PM EDT - 3 months ago

4D Molecular Therapeutics, Inc. (FDMT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 2, 2025, 8:00 AM EDT - 3 months ago

4DMT Announces Leadership Expansion with Proven Late-Stage Executives to Drive 4D-150 Execution and BLA Readiness

Aug 25, 2025, 8:00 AM EDT - 3 months ago

4DMT to Participate in Upcoming Investor Conferences

Aug 11, 2025, 8:00 AM EDT - 4 months ago

4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

Aug 6, 2025, 8:00 AM EDT - 4 months ago

4DMT to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 1, 2025, 10:29 AM EDT - 4 months ago

4D Molecular Therapeutics Rallies On Heels Of Diabetes-Related Vision Study

Jul 31, 2025, 4:05 PM EDT - 4 months ago

4DMT Presents Positive 60-Week Results from 4D-150 SPECTRA Clinical Trial in DME and Regulatory Update

Jul 24, 2025, 8:00 AM EDT - 4 months ago

4DMT Announces Presentations at 43rd Annual Scientific Meeting of the American Society of Retina Specialists

Jul 2, 2025, 4:05 PM EDT - 5 months ago

4DMT Announces Accelerated 4D-150 Phase 3 Development in Wet AMD and Streamlined Organization to Drive Late-Stage Execution

May 8, 2025, 4:05 PM EDT - 7 months ago

4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

May 1, 2025, 8:00 AM EDT - 7 months ago

4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DME

Mar 10, 2025, 8:00 AM EDT - 9 months ago

4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD

Feb 28, 2025, 4:05 PM EST - 9 months ago

4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

Feb 18, 2025, 2:33 PM EST - 10 months ago

4D Molecular Therapeutics: A Smart Bet On Long-Term VEGF Suppression

Feb 10, 2025, 10:26 AM EST - 10 months ago

Eye Disease Focused 4D Molecular Therapeutics Lays Out 52-Week Results From Wet AMD Study

Feb 8, 2025, 2:30 PM EST - 10 months ago

4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program

Nov 13, 2024, 4:05 PM EST - 1 year ago

4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

Nov 4, 2024, 11:00 AM EST - 1 year ago

4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Encourages Investor Participation

Nov 2, 2024, 11:00 AM EDT - 1 year ago

4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Investors To Reach Out

Oct 30, 2024, 11:00 AM EDT - 1 year ago

4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Impacted Investors To Reach Out

Oct 28, 2024, 11:00 AM EDT - 1 year ago

4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Investors To Take Part

Oct 18, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Encourages Investors To Help Investigate 4D Molecular Therapeutics Inc For Possible Securities Fraud

Oct 16, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Urges Investor Participation In An Investigation Into 4D Molecular Therapeutics Inc For Securities Fraud

Oct 14, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Urges Investors To Help Investigate Whether 4D Molecular Therapeutics Inc Committed Securities Fraud

Oct 12, 2024, 11:00 AM EDT - 1 year ago

4D Molecular Therapeutics Inc Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Impacted Investors To Reach Out

Oct 10, 2024, 11:00 AM EDT - 1 year ago

4D Molecular Therapeutics Inc Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Investor Participation

Oct 8, 2024, 11:00 AM EDT - 1 year ago

4D Molecular Therapeutics Inc Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Affected Investors To Reach Out

Oct 6, 2024, 11:00 AM EDT - 1 year ago

4D Molecular Therapeutics, Inc. Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Affected Investors To Reach Out

AtomicAIerts Dec. 5 at 10:50 AM

$FDMT AtomicAlerts Scalp Alert Direction: SHORT Entry: $11.2 TP1: $10.5 | TP2: $9.8 | TP3: $9.1 Stop Loss: $11.8 👉 https://atomicalerts.com

0 · Reply

Iightning Dec. 5 at 5:52 AM

1ightning® Premium Options Alert (Actionable) Ticker: $FDMT Contract: Dec 19 $12C Entry: 2.62 Exit: 3.24 Return: +23.59% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Iightning Dec. 4 at 11:41 PM

1ightning® Premium Options Alert (Actionable) Ticker: $FDMT Contract: Dec 19 $12C Entry: 2.62 Exit: 3.24 Return: +23.59% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Emremumcu01 Dec. 4 at 12:24 PM

1 · Reply

HedgeAlerts Dec. 4 at 7:35 AM

0 · Reply

Iightning Dec. 4 at 7:21 AM

1ightning® Premium Options Alert (Actionable) Ticker: $FDMT Contract: Dec 19 $10C Entry: 2.70 Exit: 3.71 Return: +37.30% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

ReturnOfEsquire Dec. 4 at 2:03 AM

$FDMT Presentation still isn't up.

0 · Reply

Emremumcu01 Dec. 3 at 3:05 PM

$FDMT who’s tuning into the conference call today something tells me there will be interesting information shared with us

1 · Reply

grizzly3 Dec. 3 at 2:32 AM

$FDMT “Shot the bear”? More like ricochet back at caronte. Every time he calls for $40–$100, the chart answers with another leg down.

0 · Reply

LiquidThetaOptions Dec. 3 at 12:58 AM

0 · Reply

caronte Dec. 2 at 8:51 PM

$FDMT shot the bear, 40$ short term, 100$+ long term

0 · Reply

grizzly3 Dec. 2 at 4:54 PM

$FDMT $VKTX “Strong correlation”? No. VKTX is a high-liquidity obesity/NASH rocket coming off a huge run, FDMT is a thin gene-therapy name that just got diluted and is rolling over with no real catalysts till 2027. As usual, clown-pumper caronte is forcing a pattern that isn’t there.

0 · Reply

caronte Dec. 2 at 4:21 PM

Is it correct that I see a strong correlation between $FDMT and $VKTX charts?

0 · Reply

Iightning Dec. 2 at 1:44 AM

**1ightning® Premium Options Alert (Actionable)** **Ticker:** $FDMT **Contract:** Dec 19 $11C **Entry:** 1.05 **Exit:** 1.35 **Return:** **+29.00% ROI** This is the level of accuracy our VIP desk delivers daily. If you want **institutional-grade scalps without the noise**, join us. **Unlock VIP Access → https://1ightning.com**

0 · Reply

grizzly3 Dec. 2 at 12:22 AM

$FDMT As usual, caronte has no clue. Dreaming of a $13 “short squeeze” while the tape says the opposite. Any Dec 3 Evercore splash will be brief — after that, the trend just resumes down.

0 · Reply

Emremumcu01 Dec. 1 at 11:14 PM

$FDMT yes 10 percent loss is bad but you have to take into account every single bio tech is down atleast 5 percent or more

0 · Reply

HedgeAlerts Dec. 1 at 10:29 PM

Hedge Alert Live - Protect Your Portfolio Contract: $FDMT $10.00 Put · DEC 19, 2025 Exp Entry Price: $0.45 - $0.50 Exit Price Target: $1.00 Profit Margin: +123% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

caronte Dec. 1 at 5:45 PM

$FDMT would be nice to see it closing at 13 today. squeeze the shorts

0 · Reply

Emremumcu01 Dec. 1 at 5:19 PM

$FDMT shorts cashing in. Not worried one bit

2 · Reply

ReturnOfEsquire Dec. 1 at 4:38 PM

$FDMT If six months ago we knew we'd be in 11s with cystic fibrosis data and updates coming this month, we all would have celebrated.

1 · Reply

McMillion1 Nov. 30 at 2:48 PM

$FDMT would you sell your shares if you were 150% up, or hold for a move to $20?

2 · Reply

Doozio Nov. 29 at 5:04 PM

$FDMT it was always 🐒🍌🧠⏰♾️ wen STOKs worth MLYS become BILI’s. Barring a faatch 💣

0 · Reply

Market Cap	578.78M
Revenue (ttm)	40,000.00
Net Income (ttm)	-160.87M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-402,175.00%
Debt to Equity Ratio	0.00

Volume	699,100
Avg Vol	874,388
Day's Range	N/A - N/A
Shares Out	57.14M
Stochastic %K	40%
Beta	2.96
Analysts	Strong Sell
Price Target	$33.11